How it works, simply
It activates a receptor in the intestine that increases fluid secretion and helps stool move.
What the evidence tells us
This oral product is not an injectable peptide-vial treatment; age and diagnosis restrictions matter.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Diarrhea and dehydration are important risks.
- The label contains a pediatric dehydration warning and age-specific restrictions.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates intestinal guanylate cyclase-C to increase fluid secretion and transit.
Sponsor or developer: AbbVie / Ironwood
Studied or labeled topics: Irritable bowel syndrome with constipation, Chronic idiopathic constipation
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: LINZESS prescribing information ↗ · Regulator · Jun 01, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.